Lisa Ferrara, Ph.D., brings over 30 years of experience in orthopaedic medical device innovation and regulatory strategy in the USA Dr Ferrara will play a pivotal role in advancing Renovos’ lead product RENOVITE® BMP-2 through FDA regulatory approval in the USA RENOVITE® is a synthetic, biodegradable nanoclay carrier that is a novel therapeutic delivery platform […]
aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent, living vessel EINDHOVEN, The Netherlands, 13 June 2024 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces that it has gained approval from the US […]
Autotaxin inhibitor, IOA-289, recently received the proposed INN cambritaxestat Cambritaxestat is in the Phase I AION-02 trial in combination with chemotherapy in metastatic pancreatic cancer It is the first autotaxin inhibitor to be investigated in cancer patients Amsterdam, The Netherlands and Geneva, Switzerland, 7 March 2024 – iOnctura, a pioneering, clinical-stage biotechnology company developing transformative cancer […]
RENOVITE® BMP-2 is being developed as an alternative to bone graft materials for interbody spinal fusion It is the first product based on RENOVITE®, Renovos’ novel nanoclay therapeutic delivery platform for precision regenerative medicine Keele, UK, 4 January 2024 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating […]
Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application of VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), for the treatment of stress […]
